Fasenra granted approval in the United States for treatment of eosinophilic granulomatosis with polyangiitis.

Sep 19th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Givastomig is a pioneering first-in-class bispecific antibody immunostimulant targeting Claudin18.2 (CLDN18.2) and 4-1BB.

The FDA has greenlighted Novartis' Kisqali® to lower the chance of recurrence in patients with early-stage HR+/HER2- breast cancer.

Innovent Presents Clinical Results of IBI363 (Novel PD-1/IL-2α-bispecific Antibody) with Bevacizumab in Advanced Colorectal Cancer at 2024 ESMO Congress.

Senhwa Biosciences submits IND to FDA for NCI-sponsored Pidnarulex pharmacodynamics pilot study in advanced solid tumor patients.

Patritumab Deruxtecan showed a notable enhancement in progression-free survival compared to doublet chemotherapy in patients with advanced or metastatic EGFR-mutated NSCLC.

AC Immune Gets Another Payment After Advancing Phase 2b ReTain Trial for ACI-35.030 in Early Alzheimer’s.

This week, multinational pharmaceutical companies including Sanofi, Bayer, Gilead Sciences, Novo Nordisk, and Pfizer have been notably active.

the FDA approved several new drugs and new indications, including Roche's two blockbuster subcutaneous formulations, Eli Lilly's IL-13 antibody, and Johnson & Johnson's IL-23 antibody.

NextCure has disclosed that clinical findings from the Phase 1b segment of a Phase 1b/2 trial assessing NC410, a LAIR-2 fusion protein.

Trishula Therapeutics Shows Promising Phase 1 Results for TTX-030 in Initial Treatment of Metastatic Pancreatic Cancer.